AstraZeneca - ATTEST
Association of the risk for Thrombotic Thrombocytopenia Syndrome and Exposure To COVID19 vaccines
Aims
To evaluate an association between COVID19 vaccine exposure and thromboembolic events occurring with thrombocytopenia (thrombotic thrombocytopenia syndrome; TTS)
Deliverables
Report to regulators and scientific publications
Expected Impact
The project will shed more light on the safety of the AstraZeneca and Pfizer COVID-19 vaccines
How does this research try to address the problem?
Using the ORCHID RCGP RSC primary care data linked to national secondary care hospital admissions, ONS mortality, vaccination and testing data, we will design a matched case-control study and a self-controlled case series to learn about the safety of the AstraZeneca and Pfizer vaccines.
How we are planning to implement the research outputs
The findings of these analyses will be compiled in a report to the regulators and various scientific publications.
-
Simon de Lusignan
Professor of Primary Care and Clinical Informatics
-
Sneha Anand
Project Manager
-
Mark Joy
Chief Statistician
-
Xuejuan Fan
SQL Developer/Data Scientist
-
Filipa Ferreira
Senior Project Manager
-
Debasish Kar
Senior Clinical Researcher
External project members
Debborah Layton
Lisa Mather
Andrew Lee
Aleksandra Graduszyńska
Project end date
The analyses are complete. The report to the regulators is expected to be completed in June 2023, scientific publications during the summer of 2023
Partners on this project
AstraZeneca